Wall Street is positive on Viking Therapeutics Inc (VKTX). On average, analysts give VKTX a Strong Buy rating. The average price target is $18.25, which means analysts expect the stock to rise 391.91% over the next twelve months. This average ranking earns VKTX an analyst rating of 72, which is better than 72% of stocks based on data compiled by InvestorsObserver.
Why are analyst ratings important?
Analysts know better than anyone the inner workings of the companies they follow, with the exception of the management of the companies. You can tell a lot about a company by studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in any part of the world can disrupt supply chains or disrupt shopping habits. This allows traders to make decisions **ahead** of a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all analysts covering a given security, takes the average of these ratings, and then ranks the averages into percentiles. This provides a much better level of granularity than the three levels provided by traditional buy/hold/sell notations.
What’s going on with Viking Therapeutics Inc shares today?
Viking Therapeutics Inc (VKTX) stock is trading at $3.71 at 10:19 a.m. on Monday, January 31, an increase of $0.13, or 3.49% from the previous closing price of 3, $58. The stock has traded between $3.59 and $3.73 so far today. Today, the volume is below average. So far, 369,793 shares have been traded with an average volume of 1,098,168 shares. Click here for the full Viking Therapeutics Inc. stock report.
Stay in the know
Subscribe to our daily morning update newsletter and never miss market news, moves and more.